Mateon Therapeutics (MATN) & Anavex Life Sciences (AVXL) Financial Survey
Mateon Therapeutics (OTCMKTS: MATN) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
This table compares Mateon Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences||N/A||-95.68%||-84.88%|
Institutional & Insider Ownership
23.3% of Anavex Life Sciences shares are held by institutional investors. 4.5% of Mateon Therapeutics shares are held by company insiders. Comparatively, 11.6% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Mateon Therapeutics and Anavex Life Sciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||N/A||-$13.65 million||($0.56)||-0.40|
|Anavex Life Sciences||N/A||N/A||-$14.73 million||($0.39)||-9.74|
Anavex Life Sciences is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Mateon Therapeutics and Anavex Life Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences||0||0||2||0||3.00|
Mateon Therapeutics currently has a consensus target price of $1.75, indicating a potential upside of 686.52%. Anavex Life Sciences has a consensus target price of $15.00, indicating a potential upside of 294.74%. Given Mateon Therapeutics’ higher possible upside, analysts plainly believe Mateon Therapeutics is more favorable than Anavex Life Sciences.
Risk and Volatility
Mateon Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Anavex Life Sciences beats Mateon Therapeutics on 6 of the 10 factors compared between the two stocks.
About Mateon Therapeutics
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.